MOTS-c tracker
Educational reference for MOTS-c. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
1 h
Tmax
0.5 h
Category
peptide
> PLACEHOLDER — pending clinical review by licensed pharmacist. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by the mitochondrial genome. It has been shown in preclinical studies to activate AMPK signalling, improve insulin sensitivity, and counteract age-related metabolic decline. Its half-life is approximately 1 hour in rodent models. As a mitochondrial peptide, it represents a relatively new class of signalling molecules whose human pharmacokinetics and long-term safety remain under investigation. Users should track dosing protocols, metabolic markers, and any effects on energy levels or body composition.
Mechanism
A mitochondrial-derived peptide encoded in the mitochondrial genome. In preclinical research it has been associated with regulation of metabolic homeostasis and insulin sensitivity, partly via AMPK signaling; the mechanism and relevance in humans are still being characterized.
Research summary
Evidence is largely preclinical and mechanistic, exploring roles in exercise physiology, metabolism, and aging biology. It is not an FDA-approved drug, and human clinical trial data are limited. Claims should be read against that evidence gap. In July 2026 an FDA advisory committee (the Pharmacy Compounding Advisory Committee) voted to recommend this compound for the 503A bulk-compounding list. That recommendation is non-binding and is not FDA approval — it would still require formal rulemaking, and no approved clinical evidence of safety or efficacy exists.
Dosing in the literature
There is no established human clinical regimen and human pharmacokinetics are not well characterized. This summary does not provide dosing.
Reported side effects
Controlled human safety data are limited, so the side-effect and long-term safety profile is largely unknown. Sourcing and purity are recurring quality concerns.
Stacking notes
Discussed in metabolic and longevity research contexts, sometimes alongside other mitochondrial-derived peptides; there is no controlled human evidence supporting specific combinations.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- MOTS-c mitochondrial-derived peptide and metabolism review · peer-reviewed review article (2018)predominantly preclinical evidence; search PubMed for MOTS-c
- Regulatory status note · FDA / regulatory guidance (2024)not an approved drug; verify current status
References
- MOTS-c discovery paperDOI: 10.1016/j.cmet.2015.02.009
Track MOTS-c in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.